Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.

Atsushi Hiraoka,Yoshihiro Ishimaru,Hideki Kawasaki,Toshihiko Aibiki,Tomonari Okudaira,Akiko Toshimori,Tomoe Kawamura,Hiroka Yamago,Hiromasa Nakahara,Yoshifumi Suga,Nobuaki Azemoto,Hideki Miyata,Yasunao Miyamoto,Tomoyuki Ninomiya,Masashi Hirooka,Masanori Abe,Bunzo Matsuura,Yoichi Hiasa,Kojiro Michitaka

Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.

2015

Atsushi Hiraoka
Yoshihiro Ishimaru
Hideki Kawasaki
Toshihiko Aibiki
Tomonari Okudaira
Akiko Toshimori
Tomoe Kawamura
Hiroka Yamago
Hiromasa Nakahara
Yoshifumi Suga
Nobuaki Azemoto
Hideki Miyata
Yasunao Miyamoto
Tomoyuki Ninomiya
Masashi Hirooka
Masanori Abe
Bunzo Matsuura
Yoichi Hiasa
Kojiro Michitaka

Background/Aim: We examined tumor marker levels to assess in more detail transcatheter arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC)

Keywords:

AFP-L3
Medicine
Tumor marker
Pathology
Cancer research
Transcatheter arterial chemoembolization
Hepatocellular carcinoma
Oncology
Sorafenib
Internal medicine
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations